BR112017017529A2 - derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo - Google Patents
derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmoInfo
- Publication number
- BR112017017529A2 BR112017017529A2 BR112017017529-0A BR112017017529A BR112017017529A2 BR 112017017529 A2 BR112017017529 A2 BR 112017017529A2 BR 112017017529 A BR112017017529 A BR 112017017529A BR 112017017529 A2 BR112017017529 A2 BR 112017017529A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- chenodeoxycholic acid
- derived
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/007—Steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
a presente invenção se refere a um derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende o composto da mesma. especificamente, são revelados um derivado de ácido quenodeoxicólico deuterado representado pela fórmula (i) e uma composição farmacêutica que compreende o composto ou polimorfo da mesma, sais farmaceuticamente aceitáveis, hidratos ou solvatos. o composto acima da presente invenção é usado para tratar e/ou prevenir esteato-hepatite não alcoólica, doença hepática gordurosa não alcoólicas, cálculos biliares, cirrose biliar primária, cirrose, etc.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510084738.5 | 2015-02-16 | ||
CN201510084738.5A CN105985396A (zh) | 2015-02-16 | 2015-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
PCT/CN2016/073891 WO2016131414A1 (zh) | 2015-02-16 | 2016-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017017529A2 true BR112017017529A2 (pt) | 2018-04-17 |
Family
ID=56692502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017529-0A BR112017017529A2 (pt) | 2015-02-16 | 2016-02-16 | derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo |
Country Status (11)
Country | Link |
---|---|
US (1) | US10544185B2 (pt) |
EP (1) | EP3260463B1 (pt) |
JP (1) | JP6947644B2 (pt) |
KR (1) | KR102042112B1 (pt) |
CN (2) | CN105985396A (pt) |
AU (1) | AU2016222174B2 (pt) |
BR (1) | BR112017017529A2 (pt) |
CA (1) | CA2977109C (pt) |
HK (1) | HK1248712A1 (pt) |
RU (1) | RU2712033C2 (pt) |
WO (1) | WO2016131414A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
PL2986623T3 (pl) | 2013-04-17 | 2019-04-30 | Sage Therapeutics Inc | 19-nor C3,3-dipodstawione steroidy C21-n-pirazolilowe i sposoby ich stosowania |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
PL3021852T3 (pl) | 2013-07-19 | 2021-07-05 | Sage Therapeutics, Inc. | Neuroaktywne steroidy, kompozycje i ich zastosowania |
RU2696585C2 (ru) | 2013-08-23 | 2019-08-05 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применение |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
EP3250210B1 (en) | 2015-01-26 | 2020-12-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
ES2935476T3 (es) | 2015-02-20 | 2023-03-07 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
CN106008639B (zh) * | 2016-03-11 | 2019-01-08 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
RU2019103590A (ru) | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения |
MX2020000873A (es) | 2017-07-24 | 2020-07-22 | Intercept Pharmaceuticals Inc | Derivados de ácidos biliares marcados isotópicamente. |
KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
TW202021595A (zh) | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
PE20230244A1 (es) | 2019-05-31 | 2023-02-07 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos |
CN112142814B (zh) * | 2019-06-26 | 2021-09-28 | 江苏吉贝尔药业股份有限公司 | 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂 |
MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
CN112409435B (zh) * | 2019-08-23 | 2023-07-18 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists to treat hepatitis d virus infection |
US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
KR102490355B1 (ko) * | 2021-09-29 | 2023-01-26 | 주식회사 에이.비.아이 | 타우로케노디옥시콜산 함량이 증대된 담즙 추출물을 유효성분으로 포함하는 비만증 예방, 개선 또는 치료용 조성물 및 그의 제조방법 |
WO2024043842A1 (en) * | 2022-08-22 | 2024-02-29 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3696884B2 (ja) * | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
USRE48286E1 (en) * | 2001-03-12 | 2020-10-27 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
US20100120733A1 (en) * | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
CN106380502A (zh) | 2008-11-19 | 2017-02-08 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
PL2698375T3 (pl) * | 2008-11-19 | 2018-08-31 | Intercept Pharmaceuticals, Inc. | Modulatory TGR5 i sposób ich zastosowania |
WO2013037482A1 (en) * | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
WO2015061421A1 (en) * | 2013-10-22 | 2015-04-30 | Metselex, Inc. | Deuterated bile acids |
-
2015
- 2015-02-16 CN CN201510084738.5A patent/CN105985396A/zh active Pending
-
2016
- 2016-02-16 EP EP16751945.3A patent/EP3260463B1/en active Active
- 2016-02-16 AU AU2016222174A patent/AU2016222174B2/en active Active
- 2016-02-16 CA CA2977109A patent/CA2977109C/en active Active
- 2016-02-16 WO PCT/CN2016/073891 patent/WO2016131414A1/zh active Application Filing
- 2016-02-16 RU RU2017130849A patent/RU2712033C2/ru active
- 2016-02-16 KR KR1020177025774A patent/KR102042112B1/ko active IP Right Grant
- 2016-02-16 JP JP2017560864A patent/JP6947644B2/ja active Active
- 2016-02-16 CN CN201680010388.0A patent/CN107250149B/zh active Active
- 2016-02-16 BR BR112017017529-0A patent/BR112017017529A2/pt active Search and Examination
- 2016-02-16 US US15/551,224 patent/US10544185B2/en active Active
-
2018
- 2018-06-26 HK HK18108236.7A patent/HK1248712A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3260463A4 (en) | 2018-10-31 |
HK1248712A1 (zh) | 2018-10-19 |
RU2712033C2 (ru) | 2020-01-24 |
RU2017130849A (ru) | 2019-03-18 |
EP3260463A1 (en) | 2017-12-27 |
RU2017130849A3 (pt) | 2019-03-18 |
JP2018505220A (ja) | 2018-02-22 |
KR102042112B1 (ko) | 2019-11-08 |
US10544185B2 (en) | 2020-01-28 |
WO2016131414A1 (zh) | 2016-08-25 |
CN107250149B (zh) | 2020-11-24 |
US20180030083A1 (en) | 2018-02-01 |
CA2977109C (en) | 2020-04-14 |
CN107250149A (zh) | 2017-10-13 |
JP6947644B2 (ja) | 2021-10-13 |
EP3260463B1 (en) | 2020-09-02 |
AU2016222174A1 (en) | 2017-09-14 |
KR20170110723A (ko) | 2017-10-11 |
CN105985396A (zh) | 2016-10-05 |
AU2016222174B2 (en) | 2019-04-11 |
CA2977109A1 (en) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017017529A2 (pt) | derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo | |
CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
BR112013018601A2 (pt) | composto, uso de composto, composição farmacêutica, e, produto farmacêutico | |
BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
BR112012027385A2 (pt) | composição para o controle de doenças de plantas e uso da mesma | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
BR112020016020A8 (pt) | Inibidor de atr e aplicação do mesmo | |
NZ714203A (en) | Derivatives of dolastatin 10 and auristatins | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |